Shockwave Appoints Maria Sainz to Board of Directors
July 20 2020 - 8:00AM
Shockwave Medical, Inc. (NASDAQ: SWAV), a pioneer in the
development of Intravascular Lithotripsy (IVL) to treat complex
calcified cardiovascular disease, announced today that Maria Sainz
has joined its Board of Directors and will serve on Shockwave’s
Compensation Committee.
“I am delighted to welcome Maria to our Board of Directors,”
said Doug Godshall, President and Chief Executive Officer of
Shockwave Medical. “Her rich experience in company building and
commercialization success within the medical technology sector will
make Maria an excellent addition and invaluable strategic resource
to Shockwave as we continue to build and grow the company.”
Ms. Sainz, who has over 25 years of experience in leadership and
commercial positions in the medical technology industry, currently
serves as Chief Executive Officer of Aegea Medical, Inc. Prior to
this position, she served as the President and CEO of
Cardiokinetix, a medical device company pioneering a catheter-based
treatment for heart failure and as the President and CEO of
Concentric Medical, Inc., a developer of minimally invasive
products for the treatment of acute ischemic stroke, which was
acquired in 2011 by Stryker Corporation. Maria began her medical
technology career at Guidant Corporation where she held positions
of increasing responsibility in Europe and the United States,
culminating in her position as President of the Cardiac Surgery
division at the time of the acquisition of Guidant Corporation by
Boston Scientific. Ms. Sainz has been intimately involved in the
launches of several significant medical technology products
including coronary stents and cardiac resynchronization therapy
devices. She also serves as a member of the board of directors of
Orthofix Medical, Inc. and Avanos Medical, Inc. Ms. Sainz received
a Master of Arts in Languages from the University Complutense in
Madrid, Spain and a Masters in International Management from the
American Graduate School of International Management.
“I am honored to join the Shockwave Medical Board of Directors,”
said Ms. Sainz. “Shockwave has made tremendous progress
transforming the treatment of calcified coronary disease and I am
excited to join this esteemed group and to together collaborate
with the exceptional management team as Shockwave continues to
expand their business, commercial footprint and overall
success.”
About Shockwave Medical, Inc.
Shockwave Medical is focused on developing and commercializing
products intended to transform the way calcified cardiovascular
disease is treated. The company aims to establish a new standard of
care for the interventional treatment of atherosclerotic
cardiovascular disease through differentiated and proprietary local
delivery of sonic pressure waves for the treatment of calcified
plaque, which the company refers to as Intravascular Lithotripsy
(IVL). IVL is a minimally invasive, easy-to-use and safe way to
significantly improve patient outcomes. To view an animation of the
IVL procedure and for more information, visit
www.shockwavemedical.com.
Forward-Looking Statements.This press release
contains statements relating to Shockwave’s expectations,
projections, beliefs, and prospects (including statements regarding
Shockwave’s product development outlook), which are
“forward-looking statements” within the meaning of the federal
securities laws and by their nature are uncertain. Words such as
“believe,” “may,” “will,” “estimate,” “continue,” “anticipate,”
“intend,” “expect,” “plans,” and similar expressions are intended
to identify forward-looking statements. Such forward-looking
statements are not guarantees of future performance, and you are
cautioned not to place undue reliance on these forward-looking
statements. Our business and operations are subject to a variety of
risks and uncertainties and, consequently, actual results may
differ materially from those projected by any forward-looking
statements. Factors that could cause actual results to differ from
those projected include, but are not limited to: the impact of
the COVID-19 pandemic on our operations, financial
results, and liquidity and capital resources, including on sales,
expenses, supply chain, manufacturing, research and development
activities, clinical trials and employees; our ability to design,
develop, manufacture and market innovative products to treat
patients with challenging medical conditions, particularly in
peripheral artery disease, coronary artery disease and aortic
stenosis; our expected future growth, including growth in
international sales; the size and growth potential of the markets
for our products, and our ability to serve those markets; the rate
and degree of market acceptance of our products; coverage and
reimbursement for procedures performed using our products; the
performance of third parties in connection with the development of
our products, including third-party suppliers; regulatory
developments in the United States and foreign countries; our
ability to obtain and maintain regulatory approval or clearance of
our products on expected timelines; our plans to research, develop
and commercialize our products and any other approved or cleared
product; our ability to scale our organizational culture of
cooperative product development and commercial execution; the
development, regulatory approval, efficacy and commercialization of
competing products; the loss of key scientific or management
personnel; our expectations regarding the period during which we
qualify as an emerging growth company under the JOBS Act; our
ability to develop and maintain our corporate infrastructure,
including our internal controls; our financial performance and
capital requirements; and our expectations regarding our ability to
obtain and maintain intellectual property protection for our
products, as well as our ability to operate our business without
infringing the intellectual property rights of others. These risks
and uncertainties, as well as others, are discussed in greater
detail in our filings with the Securities and Exchange Commission
(SEC), including in Part I, Item IA - Risk Factors in our most
recent Annual Report on Form 10-K filed with the SEC, and in our
other periodic and other reports filed with the SEC. There may be
additional risks of which we are not presently aware or that we
currently believe are immaterial which could have an adverse impact
on our business. Any forward-looking statements are based on our
current expectations, estimates and assumptions regarding future
events and are applicable only as of the dates of such statements.
We make no commitment to revise or update any forward-looking
statements in order to reflect events or circumstances that may
change.
Media Contact: Scott Shadiow
+1.317.432.9210sshadiow@shockwavemedical.com
Investor Contact:Debbie Kasterinvestors@shockwavemedical.com
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Aug 2024 to Sep 2024
Shockwave Medical (NASDAQ:SWAV)
Historical Stock Chart
From Sep 2023 to Sep 2024